Literature DB >> 26155430

CD14+ macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: A new therapeutic lead?

A Marijne Heeren1, Gemma G Kenter2, Ekaterina S Jordanova3, Tanja D de Gruijl4.   

Abstract

A number of studies point to an aberrant differentiation and accumulation of CD14+ PD-L1+ M2-macrophage-like cells in the microenvironment of cervical cancer, which promote immunosuppressive conditions and are associated with tumor invasion, angiogenesis and metastasis. Therapeutic targeting of these macrophages may tip the balance in favor of antitumor immunity. Cervical cancer is the fourth most common cancer among women worldwide and is caused by a persistent infection and subsequent integration of high-risk types of the human papillomavirus. Continuous expression of the viral oncoproteins E6 and E7 has been shown essential to maintain the transformed state of infected keratinocytes. As these non-self oncoproteins are immunogenic, cervical cancer requires a highly immune suppressed tumor microenvironment to metastasize through lymphovascular space invasion (LVSI) to the pelvic tumor-draining lymph nodes (TDLN). Unraveling the mechanisms underlying this immune suppression may uncover novel therapeutic targets aimed at loco-regional control of cervical cancer.

Entities:  

Keywords:  COX, cyclooxygenase; DC, dendritic cell; IL, interleukin; LVSI, lymphovascular space invasion; MDSC, myeloid-derived suppressor cells; PD-L1; PD-L1, programmed death-ligand 1; PGE2, prostaglandin-E2; TDLN, tumor-draining lymph node; Treg, regulatory T cell; cervical cancer; dendritic cells; immunotherapy; macrophages; tumor microenvironment; tumor-draining lymph nodes

Year:  2015        PMID: 26155430      PMCID: PMC4485785          DOI: 10.1080/2162402X.2015.1009296

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  10 in total

1.  High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer.

Authors:  A Marijne Heeren; Bas D Koster; Sanne Samuels; Debbie M Ferns; Dafni Chondronasiou; Gemma G Kenter; Ekaterina S Jordanova; Tanja D de Gruijl
Journal:  Cancer Immunol Res       Date:  2014-10-31       Impact factor: 11.151

2.  Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment.

Authors:  Eveline M Dijkgraaf; Moniek Heusinkveld; Bart Tummers; Lisa T C Vogelpoel; Renske Goedemans; Veena Jha; Johan W R Nortier; Marij J P Welters; Judith R Kroep; Sjoerd H van der Burg
Journal:  Cancer Res       Date:  2013-02-22       Impact factor: 12.701

3.  M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.

Authors:  Moniek Heusinkveld; Peggy J de Vos van Steenwijk; Renske Goedemans; Tamara H Ramwadhdoebe; Arko Gorter; Marij J P Welters; Thorbald van Hall; Sjoerd H van der Burg
Journal:  J Immunol       Date:  2011-06-27       Impact factor: 5.422

4.  Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma.

Authors:  P J de Vos van Steenwijk; T H Ramwadhdoebe; R Goedemans; E M Doorduijn; J J van Ham; A Gorter; T van Hall; M L Kuijjer; M I E van Poelgeest; S H van der Burg; E S Jordanova
Journal:  Int J Cancer       Date:  2013-07-05       Impact factor: 7.396

5.  Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation.

Authors:  Claudia C Sombroek; Anita G M Stam; Allan J Masterson; Sinéad M Lougheed; Marcel J A G Schakel; Chris J L M Meijer; Herbert M Pinedo; Alfons J M van den Eertwegh; Rik J Scheper; Tanja D de Gruijl
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

6.  Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer.

Authors:  Alessandra Battaglia; Alexia Buzzonetti; Cinzia Baranello; Gabriella Ferrandina; Enrica Martinelli; Francesco Fanfani; Giovanni Scambia; Andrea Fattorossi
Journal:  Cancer Immunol Immunother       Date:  2009-01-27       Impact factor: 6.968

7.  Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?

Authors:  Ekaterina S Jordanova; Arko Gorter; Ouissam Ayachi; Frans Prins; Lindy G Durrant; Gemma G Kenter; Sjoerd H van der Burg; Gert Jan Fleuren
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

8.  Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition.

Authors:  Dinja Oosterhoff; Sinéad Lougheed; Rieneke van de Ven; Jelle Lindenberg; Hester van Cruijsen; Lotte Hiddingh; Jan Kroon; Alfons J M van den Eertwegh; Basav Hangalapura; Rik J Scheper; Tanja D de Gruijl
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

9.  Functional characterization of a STAT3-dependent dendritic cell-derived CD14+ cell population arising upon IL-10-driven maturation.

Authors:  Jelle J Lindenberg; Rieneke van de Ven; Sinéad M Lougheed; Anoek Zomer; Saskia J A M Santegoets; Arjan W Griffioen; Erik Hooijberg; Alfons J M van den Eertwegh; Victor L Thijssen; Rik J Scheper; Dinja Oosterhoff; Tanja D de Gruijl
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

10.  CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.

Authors:  Debbie C Strachan; Brian Ruffell; Yoko Oei; Mina J Bissell; Lisa M Coussens; Nancy Pryer; Dylan Daniel
Journal:  Oncoimmunology       Date:  2013-12-04       Impact factor: 8.110

  10 in total
  11 in total

Review 1.  Opportunities and challenges for human papillomavirus vaccination in cancer.

Authors:  Richard B S Roden; Peter L Stern
Journal:  Nat Rev Cancer       Date:  2018-03-02       Impact factor: 60.716

2.  Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma.

Authors:  Qian-Kun Xie; Yu-Jie Zhao; Tao Pan; Ning Lyu; Lu-Wen Mu; Shao-Long Li; Mu-De Shi; Zhen-Feng Zhang; Peng-Hui Zhou; Ming Zhao
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

3.  Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area.

Authors:  A Marijne Heeren; Eline de Boer; Maaike C G Bleeker; René J P Musters; Marrije R Buist; Gemma G Kenter; Tanja D de Gruijl; Ekaterina S Jordanova
Journal:  Oncotarget       Date:  2015-10-20

4.  The Preoperative Peripheral Blood Monocyte Count Is Associated with Liver Metastasis and Overall Survival in Colorectal Cancer Patients.

Authors:  Shidong Hu; Zhenyu Zou; Hao Li; Guijun Zou; Zhao Li; Jian Xu; Lingde Wang; Xiaohui Du
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

5.  Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels.

Authors:  A M Heeren; J Rotman; A G M Stam; N Pocorni; A A Gassama; S Samuels; M C G Bleeker; C H Mom; H J M A A Zijlmans; G G Kenter; E S Jordanova; T D de Gruijl
Journal:  J Immunother Cancer       Date:  2019-02-12       Impact factor: 13.751

Review 6.  Unlocking the therapeutic potential of primary tumor-draining lymph nodes.

Authors:  Jossie Rotman; Bas D Koster; Ekaterina S Jordanova; A Marijne Heeren; Tanja D de Gruijl
Journal:  Cancer Immunol Immunother       Date:  2019-04-03       Impact factor: 6.968

Review 7.  Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis.

Authors:  Tynisha S Rafael; Jossie Rotman; Oscar R Brouwer; Henk G van der Poel; Constantijne H Mom; Gemma G Kenter; Tanja D de Gruijl; Ekaterina S Jordanova
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

8.  Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer.

Authors:  Ying Zhang; Weipei Zhu; Xueguang Zhang; Qiuxia Qu; Liyuan Zhang
Journal:  Oncol Lett       Date:  2017-09-29       Impact factor: 2.967

9.  'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.

Authors:  J Rotman; C H Mom; E S Jordanova; T D de Gruijl; G G Kenter
Journal:  BMC Cancer       Date:  2018-09-12       Impact factor: 4.430

10.  The IFN-γ-IDO1-kynureine pathway-induced autophagy in cervical cancer cell promotes phagocytosis of macrophage.

Authors:  Shao-Liang Yang; Hai-Xia Tan; Tian-Tian Niu; Yu-Kai Liu; Chun-Jie Gu; Da-Jin Li; Ming-Qing Li; Hai-Yan Wang
Journal:  Int J Biol Sci       Date:  2021-01-01       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.